November 6, 2019
Tokyo-based upstart SymBio Pharmaceuticals said on November 5 that its cancer drug Treakisym (bendamustine) met the primary endpoint in a Japan PIII study for an additional indication of diffuse large B-cell lymphoma (DLBCL). Treakisym in combination with rituximab delivered a...read more